Kathleen Elias
Company: Seal Rock Therapeutics
Job title: Co-founder
Seminars:
Investigating Combinational Approaches to Elevate GLP-1 Therapies: Role of 2nd Generation ASK1 Inhibitor SRT-015 Treatment for MASH Fibrosis 2:20 pm
SRT-015 is an oral compound with direct pleotropic effects on the liver including fibrotic, inflammatory and apoptosis inhibition for possible use in all MASH fibrosis stages Combination therapy with GLP-1s and other metabolic agents In a Phase 1 clinical trial, SRT-015 demonstrated pharmacokinetics that enables daily dosing with a favorable safety profileRead more
day: Conf Day 1 Track 2 PM
Panel Discussion | Translating GLP-1s, Rezmiteron, FGF21 Therapies into Clinical Practice Guidelines in a Rapidly Changing Landscape 3:30 pm
Assessing how emerging therapies fit into the standard of care Navigating the future of combination therapies to optimize treatment Evaluating how this will play out in the real world with access, non-responders, standard of care and the shift to primary care providersRead more
day: Conf Day 1 EOD